1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
HUMEDIX Co.LTD.

HUMEDIX Co.LTD.

KKRX:200670
23,700.00
KRW
+100.00
(+0.42%)
4,884.34EPS
6.86P/E
372.49BMarket Cap
Nov 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,241.79
4,491.93
4,457.17
4,764.94
5,637.06
6,780.44
8,254.08
10,361.2
11,803.6
13,283.41
15,411
15,647.4
16,474.74
16,225.05
Basic EPS, GAAP
1,646.14
1,022.39
1,229.53
1,038.72
1,229.91
963
1,094
1,587
963.99
2,274
2,512
3,795
5,017
4,888.58
Free Cash Flow per Basic Share
697.97
927.9
92.17
-1,495.13
-1,105.41
714.78
469.2
638.66
472.31
3,329.32
2,211.88
4,067.53
3,597.54
3,328.15
Dividend per Share
- -
- -
- -
262.4
441.76
539.15
560.91
500.94
400.18
405.54
716.44
575.16
1,048.8
706.38
Book Value per Share
1,636.97
6,034.76
11,067.55
11,319.46
11,735.69
11,916.72
11,769.6
12,768.22
13,398.54
15,205.3
19,053.66
22,158.99
26,983.9
27,976.1
Tangible Book Value per Share
1,581.34
5,978.28
11,002.2
11,230.79
11,639.85
11,392.11
11,332.7
12,029.15
13,059.85
14,872
18,805.69
21,928.73
26,772.51
27,777.84
Basic Weighted Avg Shares
6
6
9
10
10
10
10
10
9
9
10
10
10
11
Sales/Revenue/Turnover
23,544
29,182
42,133
47,134
54,727
64,832
78,619
98,481
110,992
123,173
152,274
161,873
170,053
170,434
Operating Margin (%)
31.98
27.46
33.35
27.24
22.68
16.49
16.89
16.9
14.41
21.14
24.5
26.65
24.89
23.36
Depreciation Expense
1,190
1,239
1,502
2,236
4,158
7,106
8,880
10,520
12,274
11,493
11,277
11,471
10,911
10,285
Net Income, GAAP
9,137
6,642
11,623
10,275
11,940
9,208
10,420
15,084
9,065
21,086
24,821
39,259
51,786
51,352
Effective Tax Rate (%)
- -
17.06
22.42
16.07
15.98
8.98
7.75
15.23
11.36
27.03
23.42
18.81
18.85
21.31
Profit Margin (%)
38.81
22.76
27.59
21.8
21.82
14.2
13.25
15.32
8.17
17.12
16.3
24.25
30.45
30.13
Working Capital
11,027
44,669
76,621
73,855
53,857
40,092
39,335
50,585
90,318
55,766
110,749
140,678
158,638
159,976
LT Debt
- -
- -
- -
9,225
3,938
- -
182
256
31,923
2,437
1,755
1,305
132
118
Total Equity
14,707
53,640
109,802
113,008
113,909
113,678
121,372
134,877
141,952
139,110
198,063
228,532
299,588
310,604
Return on Invested Capital (%)
- -
19.53
13.2
9.11
8.37
8.03
10.17
10.07
8.53
10.65
14.86
15.91
12.63
11.1
Return on Capital (%)
- -
20.09
14.24
8.64
8.24
6.44
7.27
9.44
6.08
13.35
13.81
18.19
19.47
18.57
Return on Common Equity (%)
- -
19.48
14.22
9.39
11
8.6
9.55
12.99
7.37
15.91
14.72
18.41
19.61
18.69

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,527
1,229
860
LT Borrowings
- -
- -
- -
LT Finance Leases
245
132
118
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
11
Market Capitalization
553,414
447,985
372,488

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
182,989
179,243
182,745
Cash, Cash Equivalents & STI
124,989
124,908
125,290
Accounts Receivable, Net
28,459
29,265
29,513
Inventories
25,583
21,388
22,647
Total Current Liabilities
19,857
20,605
22,769
Payables & Accruals
- -
- -
- -
ST Debt
1,527
1,229
860
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.35%
18.42%
31.09%
Free Cash Flow
-136.74%
123.97%
-11.75%
Net Income, GAAP
24.02%
40.1%
31.91%
Sales/Revenue/Turnover
15.16%
11.73%
5.05%
Total Cash Common Dividend
- -
26.64%
81.94%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
41,174
45,862
37,370
37,468
161,873
2025
40,139
42,979
40,913
46,021
170,053
2026
40,521
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
891
1,143
665
1,096.11
3,795
2025
1,302
765
2,198
758.52
5,017
2026
1,171
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
300.89
- -
575.16
2025
- -
- -
150.76
569.84
1,048.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Min-Jong Kang
Full Time Employees
377
Sector
Health technology
Industry
Pharmaceuticals: major
Address
603, 268, Hagui-ro Anyang-si GY South Korea 13449
IPO Date
Dec 26, 2014
Website
humedix.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Humedix Co., Ltd. manufactures and sells pharmaceutical products, medical devices, cosmetics, active pharmaceutical ingredients and health functional foods primarily in South Korea. The company offers prescription medicines including arthritis treatments and anticancer drugs; hyaluronic acid-based dermal fillers such as Elravie Premier; botulinum toxin products including Hutox and Liztox; mesotherapy medical devices such as Dermashine Pro and Derma Elravie; skin boosters including Elravie Re2O based on acellular allogeneic dermis and Reedle Booster; bio cosmeceuticals such as cell exosomes; and various aesthetic dermatological skincare solutions. Humedix operates in the healthcare sector with a focus on aesthetics, dermatology and therapeutics, targeting hospitals, clinics and dermatology professionals across domestic and international markets including Russia, China, Brazil, Saudi Arabia, Lebanon and Southeast Asia. Founded in 2002 and headquartered in Seongnam-si, South Korea, the company changed its name from HVLS Co., Ltd. in 2010 and functions as a subsidiary within the Huons Group. Recent developments include signing an exclusive sales agreement for Reedle Booster with Evov Therapeutics in August 2025 to strengthen its aesthetics portfolio; launching skin booster Elravie Re2O in November 2024 via a distribution deal with L&C Bio; securing marketing authorization for Elravie Premier HA filler in Russia; announcing a 5 billion won treasury stock acquisition in May 2025; and signing HA filler supply contracts at Dubai Derma 2025 for Middle Eastern markets.